STAT | Reporting from the frontiers of health and medicine 中文 关注 STAT+：学者岩（Scholar Rock）获 FDA 批准，首款针对脊髓性肌萎缩症肌肉流失的药物获批 一项晚期临床试验发现，与针对 SMN2 的药物联合使用时，Isembyld 使年轻患者在一年后运动技能得到改善。 STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss statnews.com STAT | Reporting from the frontiers of health and medicine 中文 RSS thenote.app
